X

Drug Profile

HS 10384

Alternative Names: HS-10384

Latest Information Update: 12 Jan 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hansoh Pharmaceutical
Class
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Vasomotor symptoms

Most Recent Events

14 Nov 2023 Preclinical trials in Vasomotor symptoms in China (PO), prior to November 2023
12 Nov 2023 Phase-I clinical trials in Vasomotor symptoms in China (PO) (NCT06122181)
08 Nov 2023 Jiangsu Hansoh Pharmaceutical plans a phase I trial for Vasomotor symptoms in China in November 2023 (PO) (NCT06122181)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com